We are excited to offer inclusions in 6 open label clinical studies with masitinib oral route in the following indications:
• All cancers - combination masitinib/vinblastin
• All cancers - combination masitinib/gemcitabin
• Splenic hemangiosarcoma (dogs naïve of treatment) - masitinib, doxorubicin, combination masitinib/doxorubicin
• T cell lymphoma (dogs naïve of treatment) - masitinib, doxorubicin, combination masitinib/doxorubicin
• Melanoma (dogs naïve of treatment) - combination masitinib/doxorubicin, vaccine
• Melanoma expressing mutated c-kit (dogs naïve of treatment) - masitinib, vaccine
Masitinib is a registered therapy in Europe to treat unresectable Mast Cell Tumors in dogs. Masitinib is a Tyrosine Kinase Inhibitor that selectively inhibits c-kit, PDGFr and Lyn.
Main exclusion criteria are: Dogs less than 6 months of age or weighing less than 3.5 kg (7.7 lb), with cardiac insufficiency, evidence of gastric bleeding, other serious disease or prior history of kidney disease.
Trial Support/Funding Includes: The studies are partially funded.
For more details: Please contact Maria Salas or Dr. Gerald Post at 203-838-6626.
to download a PDF file with the above and more information. |